Global /China /Healthcare /Biotechnology /688670

Jiangsu Gdk Biological Technology Co., Ltd.

688670

• SSE: 688670 • Delayed

17.92CNY 1.1%

2.65 USD

As of 15 June 2026, Jiangsu Gdk Biological Technology Co., Ltd. has a market cap of $322.77M USD, ranking #18146 globally and #5539 in China. It ranks #1648 in the Healthcare sector, and #314 in the Biotechnology industry.

Global Rank

18146

Country Rank

5539

Sector Rank

1648

Industry Rank

314

Key Stats

Market Cap

$322.77MUSD

2.18B CNY

Enterprise Value

$315.58MUSD

2.14B CNY

Revenue (TTM)

$16.3MUSD

110.32M CNY

EBITDA (TTM)

-$20.45MUSD

-138.37M CNY

Net Income (TTM)

-$27.08MUSD

-183.27M CNY

EBITDA Margin

-125%

Profit Margin

-166%

PS Ratio

19.8

PB Ratio

2.0

Company Profile

Country (HQ)

China

Sector

Healthcare

Industry

Biotechnology

CEO

Jianhui Zhang open_in_new

Employees

449

Founded

2008

Website

gdkbio.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
1.1%	6.2%	1.8%	-18%	9.5%	-11%	57%	-59%	-77%

News

Markets

Exchange	Ticker	Price	Quotes
Shanghai Stock Exchange (SSE / SHA) MIC: XSHG PRIMARY	688670 江苏金迪克生物技术股份有限公司 Class A ISIN: CNE100004NR4 Shares Out.: Shares Outstanding: 123.2M¹ Shares Float: 123.183M² TV: TradingView: SSE: 688670 SA: Stock Analysis: SHA: 688670 YF: Yahoo Finance: 688670.SS GF: Google Finance: SHA: 688670 BA: Barron's: 688670 MS: Morningstar: XSHG: 688670	17.92 CNY	TV: TradingView: SSE: 688670 SA: Stock Analysis: SHA: 688670 YF: Yahoo Finance: 688670.SS GF: Google Finance: SHA: 688670 BA: Barron's: 688670 MS: Morningstar: XSHG: 688670

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Jiangsu Gdk Biological Technology Co., Ltd.

Jiangsu Gdk Biological Technology Co., Ltd engages in the research, development, production, and sale of human vaccines. The company offers quadrivalent influenza virus split vaccines. Its human vaccine products are used for the prevention of various infectious diseases, including influenza, rabies, chickenpox, herpes zoster, and pneumonia. The company was founded in 2008 and is based in Taizhou, China.

Similar Companies

Industry: Biotechnology (China)

Name	Market Cap (USD) diff.	PE	Country
WuXi Biologics (Cayman) Inc. SHEK: 2269	$17.45B 136.71B HKD 5K%	25.3	China
CSPC Pharmaceutical Group Ltd. SHEK: 1093	$12.2B 95.58B HKD 4K%	22.1	China
Sichuan Kelun Pharmaceutical Co., Ltd. SHE: 002422	$8.01B 54.23B CNY 2K%	34.4	China
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. SSE: 603392	$7.34B 49.69B CNY 2K%	-	China
3SBio Inc. SHEK: 1530	$7.08B 55.5B HKD 2K%	5.8	China
Hangzhou Tigermed Consulting Co., Ltd. SHE: 300347	$6.73B 45.52B CNY 2K%	61.6	China

Industry: Biotechnology (Global)

Name	Market Cap (USD) diff.	PE	Country
Amgen Inc. NASDAQ: AMGN	$182.42B 56K%	23.9	United States
Gilead Sciences, Inc. NASDAQ: GILD	$159.92B 49K%	19.0	United States
argenx SE EBR: ARGX	$47.89B 41.39B EUR 15K%	39.9	Netherlands
Samsung Biologics Co.,Ltd. KRX: 207940	$44.92B 68.19T KRW 14K%	35.5	South Korea
CSL Ltd. ASX: CSL	$42.46B 60.27B AUD 13K%	29.3	Australia
Lonza Group AG SIX: LONN	$42.17B 33.71B CHF 13K%	37.2	Switzerland

chevron_leftBack